# Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

> **NCT05907382** · PHASE1 · UNKNOWN · sponsor: **Jemincare** · enrollment: 80 (estimated)

## Conditions studied

- Safety and Tolerability

## Interventions

- **DRUG:** JMKX003002 will be administered orally
- **DRUG:** JMKX003002 will be administered orally
- **DRUG:** JMKX003002 will be administered orally
- **DRUG:** Placebo in Cohorts 1 to 5
- **DRUG:** Placebo in 2 Cohorts

## Key facts

- **NCT ID:** NCT05907382
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-09
- **Primary completion:** 2023-12
- **Final completion:** 2024-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907382, "Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05907382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*